Gilead Sciences Is Licensing Its Newest Hiv Drug Candidate, Bictegravir, To The U.N.-Backed Medicines Patent Pool, Meaning It Will Be Produced And Sold At A Lower Cost In 116 Low- And Middle-Income Countries Once It Is Approved.Gilead Said It Will Include The Hiv-1 Candidate In Its Existing Agreements With Generic Drugmakers Sun Pharmaceutical Industries, Strides Shasun, Mylan And Sequent Scientific, As A Single Agent Or In Fixed-Dose Combinations With Other Hiv Medicines,
